Bank of America says it spends more than $250 million a year on GLP-1 weight-loss drugs for employees

Bank of America’s CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, citing the rising cost of the prescription medications used for weight management and related health conditions.

The disclosure, reported in a market news item, puts a number on a benefit that has become a flashpoint for large employers as demand grows for medications such as GLP-1s. While the CEO characterized the cost as significant, he also said it is a worthwhile investment, tying the spending to broader workplace outcomes rather than treating it as a purely medical expense.

For employers, GLP-1 coverage has moved from a niche offering to a mainstream benefits question, as plan administrators navigate drug pricing, utilization rates, and patient eligibility rules. The company’s statement indicates that for at least some large institutions, those pressures are now reaching eye-catching, headline-level totals.

Bank of America did not, in the reporting referenced here, provide additional breakdowns such as how many employees are covered, what share of the workforce is using GLP-1s, or how the $250 million figure is allocated across plan types, geographies, or specific drug brands.

The statement also does not specify whether the bank’s costs reflect only the cost of the drugs themselves or also include related services and pharmacy administration. It likewise does not describe whether spending is being managed through controls like prior authorization criteria, tiering, or limits on duration of use.

Even without those details, the magnitude of the annual figure underscores how quickly corporate health benefits can become a major line item when clinical demand shifts and drug costs rise. For a large employer, employee benefit strategy can influence recruitment, productivity, and retention, outcomes CEOs often connect to health initiatives.

What is not clear from the cited report is whether Bank of America expects the spending to continue increasing, stabilize, or decline as pricing, utilization, or plan design changes. The company did not offer forward guidance in the material referenced here, and it did not disclose any specific targets for utilization, cost-sharing, or employee outcomes.

Investors and benefits observers will likely watch for additional disclosures in earnings materials or benefits updates, including any discussion of how the bank manages pharmacy spend and what metrics, if any, it uses to evaluate whether GLP-1 coverage is meeting its stated objectives.